Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real￤orld Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial

Post time 3 day(s) ago

journal：Journal of Gastroenterology and Hepatology

Authors：Tomomitsu Matono; Toshifumi Tada; Atsushi Hiraoka; Masashi Hirooka; Yoshiko Nakamura; Osamu Yoshida; Kazuya Kariyama; Kazuhiro Nouso; Joji Tani; Asahiro Morishita; Masanori Atsukawa; Norio Itokawa; Tomomi Okubo; Taeang Arai; Koichi Takaguchi; Akemi Tsutsui; Takuya Nagano; Ei Itobayashi; Takashi Nishimura; Shinya Fukunishi; Hirayuki Enomoto; Kunihiko Tsuji; Kazunari Tanaka; Toru Ishikawa; Kazuto Tajiri; Hironori Tanaka; Hidenori Toyoda; Yuichi Koshiyama; Chikara Ogawa; Takeshi Hatanaka; Yuki Kanayama; Satoru Kakizaki; Kazuhito Kawata; Hidenao Noritake; Atsushi Naganuma; Hisashi Kosaka; Kosuke Matsui; Masaki Kaibori; Hidekatsu Kuroda; Yutaka Yata; Hiroki Nishikawa; Michitaka Imai; Tomoko Aoki; Hironori Ochi; Hideyuki Tamai; Jumpei Okamura; Shohei Komatsu; Takanori Matsuura; Shinichiro Nakamura; Yoshihide Ueda; Soo Ki Kim; Hideko Ohama; Fujimasa Tada; Takumi Fukumoto; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada

Published date：--

DOI：10.1111/jgh.70422

PDF link：https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jgh.70422

Article link：https://doi.org/10.1111/jgh.70422

Article Source：Wiley。

Remark：

Post time 3 day(s) ago

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

Post time 3 day(s) ago

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[Wiley] Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real￤orld Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Wiley] Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real￤orld Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial Copy

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Wiley] Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real￤orld Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial